19 November 2015 - Elisabeth Prchla, general manager, Merck in the UK and Ireland, says: “We are disappointed with the preliminary NICE recommendation which in our opinion brings into question the methodology used to assess personalised medicines in patients with metastatic cancer.”

For more details, go to: http://www.pharmafile.com/news/501201/merck-criticises-nice-no-personalised-bowel-cancer-drugs?